Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | PNMT | P11086 | 2/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR2B | P41595 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5262783 | 1.00 | GLA (0.57) | GLAPNMTTAAR1SLC6A2SLC6A4 | |
| SCHEMBL2660512 | 0.87 | GLA (0.58) | GLASLC6A2SLC6A4SLC6A3FOLH1 | |
| Amphetamine SCHEMBL28349144 | 0.85 | TAAR1 (0.70) | PNMTTAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21316490 | 0.84 | GLA (0.55) | GLASLC6A2SLC6A4SLC6A3FOLH1 | |
| SCHEMBL10606037 | 0.84 | FOLH1 (0.50) | GLASLC6A2SLC6A4FOLH1DPP4 | |
| SCHEMBL22395447 | 0.84 | FOLH1 (0.50) | GLASLC6A2SLC6A4FOLH1DPP4 | |
| SCHEMBL28046794 | 0.84 | GLA (0.55) | GLASLC6A2SLC6A4SLC6A3FOLH1 | |
| SCHEMBL18648975 | 0.82 | GLA (0.54) | GLASLC6A2SLC6A4SLC6A3FOLH1 | |
| SCHEMBL30762197 | 0.82 | DPP7 (0.50) | GLASLC6A2SLC6A4FOLH1DPP4 | |
| SCHEMBL20170038 | 0.82 | GLA (0.54) | GLASLC6A2SLC6A4SLC6A3FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-23 | — | — | US | disclosed |
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504403-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1716150-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1794135-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| EP-1716150-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| WO-2006037117-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2006-03-30 | — | — | US | disclosed |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-08-25 | — | — | US | disclosed |
| WO-2005070932-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292300-A1 | DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS | TLR9, TLR7, TLR8 | GLA 4660/4885PNMT 1301/4885TAAR1 191/4885 |
| US-20050187223-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MUSK, MAPT | GLA 1653/4885PNMT 2264/4885TAAR1 2835/4885 |
| US-20060069110-A1 | Substituted heterocyclic compounds and methods of use | MAPT, MYLK2, IAPP | GLA 1588/4885PNMT 2706/4885TAAR1 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.